You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

regorafenib

Showing 1 - 25 of 321
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Colorectal Cancer Trial in Shanghai (Regorafenib, Trifluridine/Tipiracil)

Recruiting
  • Metastatic Colorectal Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 24, 2023

TAS-102 in Combination With Regorafenib or Fruquintinib for

Not yet recruiting
  • TAS 102
  • +3 more
  • (no location specified)
Aug 7, 2023

Microsatellite Stable Metastatic Colorectal Cancer Trial in Shanghai (Regorafenib, Toripalimab, High/low-dose radiotherapy)

Recruiting
  • Microsatellite Stable Metastatic Colorectal Cancer
  • Regorafenib
  • +2 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 19, 2023

MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Aug 17, 2023

Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma Trial in Padova (Regorafenib, Temozolomide)

Recruiting
  • Glioblastoma, IDH-wildtype
  • MGMT-Methylated Glioblastoma
  • Padova, Italy
    Istituto Oncologico Veneto IRCCS
Oct 18, 2023

Colorectal Cancer Liver Metastases, Regorafenib Trial in Guangdong (Regorafenib and DIBIRI, Regorafenib)

Recruiting
  • Colorectal Cancer Liver Metastases
  • Regorafenib
  • Regorafenib and DIBIRI
  • Regorafenib
  • Guangdong, Guangzhou, China
    Bo Zhang
Mar 20, 2023

Learn More About Long-Term Responses to Treatment With

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Regorafenib (Stivarga, BAY73-4506)
  • Whippany, New Jersey
    Bayer
Sep 1, 2023

Colorectal Cancer Trial (Regorafenib)

Not yet recruiting
  • Colorectal Cancer
  • Regorafenib
  • (no location specified)
Apr 17, 2023

CCR5, Microsatellite Stable, Metastatic Trial (700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at

Withdrawn
  • CCR5
  • +3 more
  • 700mg leronlimab weekly dose
  • +3 more
  • (no location specified)
Feb 15, 2023

Colorectal Cancer Trial (KN046, regorafenib)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Aug 2, 2023

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Advanced Biliary Tract Cancer Trial in Tianjin (Cadonilimab+Regorafenib+GC)

Not yet recruiting
  • Advanced Biliary Tract Cancer
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
Apr 7, 2023

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Gastrointestinal Stromal Tumors Trial in Houston (Regorafenib)

Not yet recruiting
  • Gastrointestinal Stromal Tumors
  • Regorafenib
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2023

Bone Cancer Trial in Villejuif (regorafenib tablet)

Recruiting
  • Bone Cancer
  • regorafenib tablet
  • Villejuif, Ile De France, France
    Gustave Roussy
Apr 13, 2023

Advanced Hepatocellular Carcinoma Trial in Guangzhou (Cadonilimab+regorafenib)

Active, not recruiting
  • Advanced Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Mar 6, 2023

Unresectable Hepatocellular Carcinoma, Oligometastatic Disease Trial in Beijing (SBRT plus tislelizumab and regorafenib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Oligometastatic Disease
  • SBRT plus tislelizumab and regorafenib
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Jun 15, 2023

Liver Cancer, Hepatocellular Carcinoma Trial (Regorafenib Oral Product)

Not yet recruiting
  • Liver Cancer
  • Hepatocellular Carcinoma
  • Regorafenib Oral Product
  • (no location specified)
Nov 17, 2022

Colorectal Cancer, Liver Metastases Trial in Hangzhou (Serplulimab+Regorafenib, Hepatic Artery Bicarbonate Infusion)

Not yet recruiting
  • Colorectal Cancer
  • Liver Metastases
  • Hangzhou, Zhejiang, China
    the Second Affiliated Hospital of Medical College of Zhejiang Un
Jun 7, 2023

Liver Metastasis Colon Cancer Trial in Guangzhou (TACE and HAIC Combined With Regorafenib)

Not yet recruiting
  • Liver Metastasis Colon Cancer
  • TACE and HAIC Combined With Regorafenib
  • Guangzhou, Guangdong, China
    the first affiliated hospital, Sun-Yat sen university
Oct 2, 2023

Gastrointestinal Stromal Tumors Trial in Miami (Sunitinib, Regorafenib)

Recruiting
  • Gastrointestinal Stromal Tumors
  • Miami, Florida
    University of Miami
Jan 3, 2023

Colorectal Liver Metastases Trial in Beijing (Tislelizumab, Regorafenib, HAIC)

Recruiting
  • Colorectal Liver Metastases
  • Beijing, Beijing, China
  • +1 more
May 25, 2023

Hepatocellular Carcinoma, Transcatheter Arterial ChEmoembolization, Regorafenib Trial in Guangzhou (TACE, Regorafenib)

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • TACE
  • Regorafenib
  • Guangzhou, Guangdong, China
    FirstSunYetSen
Apr 12, 2023

Colorectal Cancer, Colon Cancer, Rectum Cancer Trial in Houston (Regorafenib, XmAb20717)

Not yet recruiting
  • Colorectal Cancer
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
May 31, 2023

Hepatocellular Carcinoma (HCC) Trial in Taiwan (Chidamide, Regorafenib)

Recruiting
  • Hepatocellular Carcinoma (HCC)
  • Kaohsiung, Taiwan
  • +4 more
Mar 14, 2023